1,642
edits
Changes
Jump to navigation
Jump to search
Line 1:
Line 1: − + − The Hepatitis B vaccine, which is required by most states of children in order to be admitted to public school, reportedly increases the risk of multiple sclerosis. Note that Hepatitis B is not contagious in the school setting and is not required of school teachers. It is required of schoolchildren as a result of lobbying by the manufacturer, which makes a profit on every additional shot given. It is lucrative for a company to pass a law that requires people to buy its product!+ − − '''Recombinant hepatitis B vaccine and the risk of multiple sclerosis''' Line 10:
Line 8: − + + + + + + + − Methods: The authors conducted a nested case-control study within the General Practice Research Database (GPRD) in the United Kingdom. ...+ − Results: The analyses include 163 cases of MS and 1,604 controls. The OR of MS for vaccination within 3 years before the index date compared to no vaccination was 3.1 (95% CI 1.5, 6.3). No increased risk of MS was associated with tetanus and influenza vaccinations.+ − + − ----+ − '''References:''' <references/>+ +
no edit summary
'''Reverted to version without medical contributor'''
The '''Hepatitis B vaccine''', which is required by most states of children in order to be admitted to public school, reportedly increases the risk of multiple sclerosis. Hepatitis B is not contagious in the school setting and is not required of school teachers. It is required of schoolchildren as a result of lobbying by its manufacturer, which makes a profit on every additional shot given. It is extremely lucrative for a company to pass a law that requires people to buy its product.
==Recombinant hepatitis B vaccine and the risk of multiple sclerosis==
<br>A prospective study<ref>http://www.neurology.org/cgi/content/abstract/63/5/838</ref>
<br>A prospective study<ref>http://www.neurology.org/cgi/content/abstract/63/5/838</ref>
From the Department of Epidemiology (Dr. Hernán), Harvard School of Public Health, Boston; Boston Collaborative Drug Surveillance Program (Drs. Susan S. Jick and Hershel Jick), Boston University, Lexington, MA; and Department of Neurology (Dr. Olek), College of Medicine, University of California, Irvine.
From the Department of Epidemiology (Dr. Hernán), Harvard School of Public Health, Boston; Boston Collaborative Drug Surveillance Program (Drs. Susan S. Jick and Hershel Jick), Boston University, Lexington, MA; and Department of Neurology (Dr. Olek), College of Medicine, University of California, Irvine.
Background: A potential link between the recombinant hepatitis B vaccine and an increased risk of multiple sclerosis (MS) has been evaluated in several studies, but some of them have substantial methodologic limitations.
===Background===
A potential link between the recombinant hepatitis B vaccine and an increased risk of multiple sclerosis (MS) has been evaluated in several studies, but some of them have substantial methodologic limitations.
===Methods===
The authors conducted a nested case-control study within the General Practice Research Database (GPRD) in the United Kingdom.
===Results===
The analysis included 163 cases of MS and 1,604 controls. The OR of MS for vaccination within 3 years before the index date compared to no vaccination was 3.1 (95% CI 1.5, 6.3). No increased risk of MS was associated with tetanus and influenza vaccinations.
Conclusions: These findings are consistent with the hypothesis that immunization with the recombinant hepatitis B vaccine is associated with an increased risk of MS, and challenge the idea that the relation between hepatitis B vaccination and risk of MS is well understood.
===Conclusions===
These findings are consistent with the hypothesis that immunization with the recombinant hepatitis B vaccine is associated with an increased risk of MS, and challenge the idea that the relation between hepatitis B vaccination and risk of MS is well understood.
==References==
<references/>
[[Category:Vaccines]]
[[Category:Vaccines]]